Storytelling, Awareness, and the Race Against Time in Duchenne Muscular Dystrophy
A conversation with advocate Thomas Bartlett on why storytelling and public awareness, as much as science, drive funding, policy, and access in Duchenne.
Reported pieces and analysis on Duchenne Muscular Dystrophy: disease, care, access, and the families living it. Sources linked inline.
A conversation with advocate Thomas Bartlett on why storytelling and public awareness, as much as science, drive funding, policy, and access in Duchenne.
ELEVIDYS, the first Duchenne gene therapy, is approved in the US and Japan but rejected in Europe, leaving a child's access increasingly shaped by geography.
A reported comparison of how Duchenne families in the United States and Georgia experience access, advocacy, and the urgency of time.
A journalist's first-person account of interviewing parents of children with Duchenne muscular dystrophy in Georgia, and what the conversation revealed.
How regulators, payers, and politics meet in the Duchenne treatment access dispute in Georgia, and what it says about rare disease policy.
Inside the Duchenne movement in Georgia: families, children, daily life, and what it costs to wait.
A reported piece on Duchenne Muscular Dystrophy, access to treatment, and the role information plays in deciding who receives care in time.